Report Details

Sickle Cell Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

ID : 7745292
Date : May 2019
Pages : 201 Pages
Industry : Pharmaceutical and Healthcare


Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent.



Sickle Cell Diseases Treatment Market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as underdeveloped economies. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.



Sickle Cell Diseases Treatment Market is segmented on the basis of disease type, therapy, drug class, distribution channel, and geography.



On the basis of disease type, the global Sickle Cell Diseases Treatment Market treatment is segmented as:

Sickle beta thalassemia
Sickle haemoglobin C disease
Sickle cell anaemia
Others


On the basis of therapy, the global Sickle Cell Diseases Treatment Market is segmented as:

Bone Marrow Transplant
Blood Transfusion
Gene Therapy


On the basis of the drug class, the global Sickle Cell Diseases Treatment Market is segmented as:

Antibiotics
Analgesics
Antimetabolite Hydroxyurea
Others


On the basis of the distribution channel, the global Sickle Cell Diseases Treatment Market is segmented as:

Hospital Pharmacies
Retail Pharmacies
Others


Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD’s. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique CRISPR, researchers have replaced the SCD cell genes with one which doesn’t carry those genes. In 2016, Infosys has donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like haemophilia and sickle cell disease.



Based on the geographical regions, a global Sickle Cell Diseases Treatment Market is segmented into Latin America, Europe, North America, the Middle East and Africa, and Asia Pacific. North America is dominating the sickle cell anaemia treatment market due to the increase in activities in R&D, high accessibility of developed healthcare infrastructure and high reimbursement policies are attributing for the growth of the SCD treatment market in the region. Owing to the high prevalence rate of disease in Asia Pacific and African regions is favouring the growth of SCD treatment market. Asia-Pacific is one of the speedy growing markets due to the funding of the various industry players for stem cell research



Some of the sickle cell disease treatment providers are Biogen U.S., Gamida Cell Israel, Genetix Pharmaceuticals Inc. U.S., Sangamo Biosciences U.S., Alnylam Pharmaceuticals, Inc. U.S., Acceleron Pharma U.S., Global Blood Therapeutics Inc. U.S., Emmaus Medical, Inc. U.S., Novartis AG Switzerland and Bristol-Myers Squibb Company U.S..



In July 2018, Emmaus Medical Inc. Endari L-glutamine oral powder received U.S. FDA approval to treat the patients with age of five years and older having sickle cell disease


In 2016 Novartis AG acquired Selexys Pharmaceuticals in order to expand product offerings related to blood disorders and diseases


Report Outline:



The report provides granular level information about the market size, regional market share and forecast from 2019-2025
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. Executive summary
2. Global Sickle Cell Disease Treatment Market Introduction
2.1. Global Sickle Cell Disease Treatment Market– Taxonomy
2.2. Global Sickle Cell Disease Treatment Market–Definitions
2.2.1. Disease Type
2.2.2. Therapy
3. Global Sickle Cell Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Sickle Cell Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Sickle Cell Disease Treatment Market– Recent Market Introductions
4. Global Sickle Cell Disease Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 – 2025
4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
4.2. Year-over-Year Y-o-Y Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Sickle Cell Disease Treatment Market Forecast, By Diseases Type, 2014 - 2018 and Forecast, 2019 - 2025
5.1. Sickle Beta Thalassemia
5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Sickle Haemoglobin C Disease
5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Sickle Cell Anaemia
5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
6. Global Sickle Cell Disease Treatment Market Forecast, By Therapy, 2014 - 2018 and Forecast, 2019 - 2025
6.1. Bone Marrow Transplant
6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Blood Transfusion
6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Gene Therapy
6.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
7. Global Sickle Cell Disease Treatment Market Forecast, By Drug Class, 2014 - 2018 and Forecast, 2019 - 2025
7.1. Antibiotics
7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Analgesics
7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Antimetabolites
7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.4.3. Market Opportunity Analysis
8. Global Sickle Cell Disease Treatment Market Forecast, By End User, 2014 - 2018 and Forecast, 2019 - 2025
8.1. Hospitals
8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. Others
8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
9. Global Sickle Cell Disease Treatment Market Forecast, By Region, 2014 - 2018 and Forecast, 2019 - 2025
9.1. North America
9.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
9.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
9.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
9.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
9.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
9.5.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
9.5.3. Market Opportunity Analysis
9.6. Global Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Region, 2019 – 2025
10. North America Sickle Cell Disease Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
10.1.1. Diseases Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.1.1. Sickle Beta Thalassemia
10.1.1.2. Sickle Haemoglobin C Disease
10.1.1.3. Sickle Cell Anaemia
10.1.1.4. Others
10.1.2. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.2.1. Bone Marrow Transplant
10.1.2.2. Blood Transfusion
10.1.2.3. Gene Therapy
10.1.3. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.3.1. Antibiotics
10.1.3.2. Analgesics
10.1.3.3. Antimetabolite Hydroxyurea
10.1.3.4. Others
10.1.4. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.4.1. Hospitals
10.1.4.2. Diagnostic Centres
10.1.4.3. Blood Donation Centres
10.1.5. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn Y-o-Y Growth % and Market Share %
10.1.5.1. U.S.
10.1.5.2. Canada
10.1.6. North America Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2019 – 2025
10.1.7. North America Sickle Cell Disease Treatment Market Dynamics – Trends
11. Europe Sickle Cell Disease Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
11.1.1. Diseases Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.1.1. Sickle Beta Thalassemia
11.1.1.2. Sickle Haemoglobin C Disease
11.1.1.3. Sickle Cell Anaemia
11.1.1.4. Others
11.1.2. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.2.1. Bone Marrow Transplant
11.1.2.2. Blood Transfusion
11.1.2.3. Gene Therapy
11.1.3. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.3.1. Antibiotics
11.1.3.2. Analgesics
11.1.3.3. Antimetabolite Hydroxyurea
11.1.3.4. Others
11.1.4. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.4.1. Hospitals
11.1.4.2. Diagnostic Centres
11.1.4.3. Blood Donation Centres
11.1.5. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Spain
11.1.5.5. Italy
11.1.5.6. Russia
11.1.5.7. Poland
11.1.5.8. Rest of Europe
11.1.6. Europe Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2019 – 2025
11.1.7. Europe Sickle Cell Disease Treatment Market Dynamics – Trends
12. Asia-Pacific Sickle Cell Disease Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
12.1.1. Diseases Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.1.1. Sickle Beta Thalassemia
12.1.1.2. Sickle Haemoglobin C Disease
12.1.1.3. Sickle Cell Anaemia
12.1.1.4. Others
12.1.2. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.2.1. Bone Marrow Transplant
12.1.2.2. Blood Transfusion
12.1.2.3. Gene Therapy
12.1.3. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.3.1. Antibiotics
12.1.3.2. Analgesics
12.1.3.3. Antimetabolite Hydroxyurea
12.1.3.4. Others
12.1.4. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.4.1. Hospitals
12.1.4.2. Diagnostic Centres
12.1.4.3. Blood Donation Centres
12.1.5. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn,
Y-o-Y Growth %, and Market Share %
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of Asia-Pacific
12.1.6. Asia-Pacific Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2019 – 2025
12.1.7. Asia-Pacific Sickle Cell Disease Treatment Market Dynamics – Trends
13. Latin America Sickle Cell Disease Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
13.1.1. Diseases Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.1.1. Sickle Beta Thalassemia
13.1.1.2. Sickle Haemoglobin C Disease
13.1.1.3. Sickle Cell Anaemia
13.1.1.4. Others
13.1.2. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.2.1. Bone Marrow Transplant
13.1.2.2. Blood Transfusion
13.1.2.3. Gene Therapy
13.1.3. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.3.1. Antibiotics
13.1.3.2. Analgesics
13.1.3.3. Antimetabolite Hydroxyurea
13.1.3.4. Others
13.1.4. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.4.1. Hospitals
13.1.4.2. Diagnostic Centres
13.1.4.3. Blood Donation Centres
13.1.5. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2019 – 2025
13.1.7. Latin America Sickle Cell Disease Treatment Market Dynamics – Trends
14. Middle East & Africa Sickle Cell Disease Treatment Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
14.1.1. Diseases Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
14.1.1.1. Sickle Beta Thalassemia
14.1.1.2. Sickle Haemoglobin C Disease
14.1.1.3. Sickle Cell Anaemia
14.1.1.4. Others
14.1.2. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
14.1.2.1. Bone Marrow Transplant
14.1.2.2. Blood Transfusion
14.1.2.3. Gene Therapy
14.1.3. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
14.1.3.1. Antibiotics
14.1.3.2. Analgesics
14.1.3.3. Antimetabolite Hydroxyurea
14.1.3.4. Others
14.1.4. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
14.1.4.1. Hospitals
14.1.4.2. Diagnostic Centres
14.1.4.3. Blood Donation Centres
14.1.5. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
14.1.5.1. Gulf Cooperation Council GCC Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. MEA Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2019 – 2025
14.1.7. MEA Sickle Cell Disease Treatment Market Dynamics – Trends
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis
15.2.1. Biogen U.S.
15.2.2. Gamida Cell Israel
15.2.3. Genetix Pharmaceuticals Inc. U.S.
15.2.4. Sangamo Biosciences U.S.
15.2.5. Alnylam Pharmaceuticals, Inc. U.S.
15.2.6. Acceleron Pharma U.S.
15.2.7. Global Blood Therapeutics Inc. U.S.
15.2.8. Emmaus Medical, Inc. U.S.
15.2.9. Novartis AG Switzerland
15.2.10. Bristol-Myers Squibb Company U.S..
16. Research Methodology
17. Key Assumptions and Acronyms


Please fill the following form to know more details about this Report




RELATED PRODUCTS



CHOOSE A FORMAT


  •  Single User Price : $ 4400
  •  Enterprise User License : $ 6600
  •  Corporate User License : $ 8900

Have A Question ?


  DOWNLOAD SAMPLE



TESTIMONIALS

I am completely satisfied with the information given in the sample pages of the report and I am waiting for the affirmative response from my peers and colleagues to purchase it.hey answered to all my queries promptly. I am highly satisfied!!
John Keats
We received a very quick response to all our queries on the RTLS report and we were also given a free consult with analyst for 15 minutes. It is refreshing (and increasingly rare) to have a new company go the extra mile to win the confidence of the customer
Ernest Hemingway
I would like to express my gratitude for the excellent service received this morning from the support team. They acknowledged my concern of adding me to the secondary user's list immediately. Thank you for this excellent, speedy and thoughtful service
Jacob Watson

CUSTOM RESEARCH

Still haven't found what you're looking for ?
Speak to our Custom Research Team